Hypertension

• Dosage must be individualized. The usual starting dose of Telmisartan tablets is 40 mg once a day. Blood pressure response is dose-related over the range of 20 to 80 mg.
• Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80 mg Telmisartan is required, a diuretic may be added.
• No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis.
• Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.
• Telmisartan tablets may be administered with other antihypertensive agents.
• Telmisartan tablets may be administered with or without food.

• Telmisartan tablets are contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to Telmisartan or any other component of this product.
• Do not co-administer aliskiren with Telmisartan tablets in patients with diabetes.

• Fetal Toxicity: Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
• Hypotension: In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with Telmisartan
• Hyperkalemia: Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels.
• Impaired Hepatic Function: As the majority of Telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduced clearance. Initiate Telmisartan at low doses and titrate slowly in these patients.
• Impaired Renal Function: As a consequence of inhibiting the renin-angiotensin-aldosterone system, anticipate changes in renal function in susceptible individuals.

• Headache
• Dizziness
• Asthenia
• Hyperkalemia
• Hypotension

Store at room temperature.

TELMI 20: 10×14’s
TELMI 40: 10×10’s
TELMI 80: 10×10’s